Venous vascular pharmacology: how does it contribute to heart failure with preserved ejection fraction?

Clicks: 1
ID: 315304
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #11 of 26 articles by views in European Heart Journal - Cardiovascular Pharmacotherapy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Heart failure with preserved ejection fraction (HFpEF) is a major cause of cardiovascular morbidity and mortality globally. Despite significant research, the pathophysiological mechanisms underlying this complex condition remain poorly defined. Recently, the venous system has emerged as an underrecognized yet critical contributor to HFpEF pathogenesis, functioning as the primary capacitance system and a determinant of central venous pressure. Evidence suggests an imbalance between endothelial-derived relaxing and contractile factors (EDRF/EDCF), leading to venous endothelial dysfunction, elevated venous tone, and increased mean circulatory filling pressure, all factors that contribute to ventricular–vascular mismatch. This review synthesizes current literature on the vasoactive effects of EDRF and EDCF in the venous vs. arterial systems, in both preclinical and clinical models, and examines how HFpEF therapies may target these pathways. While preclinical models demonstrate the vasoactivity of these mediators in veins of healthy and hypertensive animals, studies investigating its effects in validated HFpEF models are lacking, prompting further research. Furthermore, clinical studies should also prioritize functional assessments and venous-specific endpoints, including direct measures of venous compliance, to better guide therapeutic strategies for HFpEF.
Reference Key
openalex_W7162769595 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jack Lineham, Misha Dagan, B Wang, D M Kaye
Journal European Heart Journal - Cardiovascular Pharmacotherapy
Year 2026
DOI
10.1093/ehjcvp/pvag024
URL
https://doi.org/10.1093/ehjcvp/pvag024
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.